letrozole has been researched along with Hyperandrogenism in 21 studies
Hyperandrogenism: A condition caused by the excessive secretion of ANDROGENS from the ADRENAL CORTEX; the OVARIES; or the TESTES. The clinical significance in males is negligible. In women, the common manifestations are HIRSUTISM and VIRILISM as seen in patients with POLYCYSTIC OVARY SYNDROME and ADRENOCORTICAL HYPERFUNCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the outcome of long letrozole therapy for induction of ovulation in patients with clomiphene-resistant polycystic ovary syndrome (PCOS)." | 9.14 | Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol. ( Badawy, A; Eid, M; Mosbah, A; Tharwat, A, 2009) |
| "The objective was to evaluate ovarian functionality and oxidative response in hyperandrogenism-induced polycystic ovary (PCO) and the protective effects of immunomodulator drug (IMOD), an electromagnetically-treated, selenium-based, herbal medicine." | 7.78 | Molecular mechanisms of a novel selenium-based complementary medicine which confers protection against hyperandrogenism-induced polycystic ovary. ( Abdollahi, M; Ahmadi, A; Baeeri, M; Rezvanfar, MA; Shojaei-Saadi, HA, 2012) |
| "letrozole for 5 treatment cycles (or approximately up to 25 weeks)." | 6.77 | The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome. ( Brzyski, RG; Casson, PR; Christman, GM; Coutifaris, C; Diamond, MP; Eisenberg, E; Kunselman, AR; Legro, RS; Santoro, N; Schlaff, WD; Taylor, HS; Zhang, H, 2012) |
| "We also investigated whether hyperinsulinemia occurs secondary to weight gain and insulin resistance in this model or if it can occur independently." | 5.46 | Hyperandrogenemia Induced by Letrozole Treatment of Pubertal Female Mice Results in Hyperinsulinemia Prior to Weight Gain and Insulin Resistance. ( Anvar, AR; Hernández-Carretero, A; Rivera, AJ; Skarra, DV; Thackray, VG, 2017) |
| " Additionally, novel cosmetic techniques like electrolysis, laser and use of topically applied eflornithine to tackle the most distressing feature of facial hirsutism associated with PCOS, non-pharmacological therapy like acupuncture and the role of herbal medicine in PCOS management have also been discussed." | 5.22 | Polycystic ovarian syndrome-current pharmacotherapy and clinical implications. ( Ali, T; Amin, F; Ara, R; Bader, GN; Kareem, O; Malik, A; Mir, SA; Rashid, R, 2022) |
| "To evaluate the outcome of long letrozole therapy for induction of ovulation in patients with clomiphene-resistant polycystic ovary syndrome (PCOS)." | 5.14 | Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol. ( Badawy, A; Eid, M; Mosbah, A; Tharwat, A, 2009) |
| " ISS boys with letrozole-induced hypergonadotropic hyperandrogenism had, after 12 months of therapy, higher INSL3 levels than did placebo treated (0." | 5.12 | Serum insulin-like factor 3 levels during puberty in healthy boys and boys with Klinefelter syndrome. ( Andersson, AM; Bay, K; Dunkel, L; Hero, M; Wikström, AM, 2006) |
| "To evaluate the effect of metformin and pioglitazone on leutinizing hormone and follicle stimulating hormone receptor mRNA expression, hyperandrogenism and insulin resistance in high fat diet induced and letrozole induced PCOS in rats." | 3.88 | Insulin Sensitizers Modulate GnRH Receptor Expression in PCOS Rats. ( Patel, R; Shah, G, 2018) |
| "The objective was to evaluate ovarian functionality and oxidative response in hyperandrogenism-induced polycystic ovary (PCO) and the protective effects of immunomodulator drug (IMOD), an electromagnetically-treated, selenium-based, herbal medicine." | 3.78 | Molecular mechanisms of a novel selenium-based complementary medicine which confers protection against hyperandrogenism-induced polycystic ovary. ( Abdollahi, M; Ahmadi, A; Baeeri, M; Rezvanfar, MA; Shojaei-Saadi, HA, 2012) |
| "letrozole for 5 treatment cycles (or approximately up to 25 weeks)." | 2.77 | The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome. ( Brzyski, RG; Casson, PR; Christman, GM; Coutifaris, C; Diamond, MP; Eisenberg, E; Kunselman, AR; Legro, RS; Santoro, N; Schlaff, WD; Taylor, HS; Zhang, H, 2012) |
| "Acne is an off-label use of some COCs." | 1.72 | Female Pelvic Conditions: Polycystic Ovary Syndrome. ( Brady, PH; Gin, GT; Rosenblum, E; Wilkinson, LD, 2022) |
| "Polycystic ovary syndrome is a common reproductive disorder in the female of reproductive age, which is characterized by hyperandrogenism, insulin resistance, cystic ovary and infertility." | 1.62 | Inhibition of visfatin by FK866 mitigates pathogenesis of cystic ovary in letrozole-induced hyperandrogenised mice. ( Annie, L; Gurusubramanian, G; Roy, VK, 2021) |
| "Hyperandrogenism is one of the major characteristics of polycystic ovary syndrome (PCOS)." | 1.56 | Decreased microRNA-125b-5p disrupts follicle steroidogenesis through targeting PAK3/ERK1/2 signalling in mouse preantral follicles. ( Cherrington, BD; E, Q; Gong, X; Han, Y; Li, T; Liu, X; Xiao, H; Xu, B; Ying, X; Zhang, X, 2020) |
| "We also investigated whether hyperinsulinemia occurs secondary to weight gain and insulin resistance in this model or if it can occur independently." | 1.46 | Hyperandrogenemia Induced by Letrozole Treatment of Pubertal Female Mice Results in Hyperinsulinemia Prior to Weight Gain and Insulin Resistance. ( Anvar, AR; Hernández-Carretero, A; Rivera, AJ; Skarra, DV; Thackray, VG, 2017) |
| "Polycystic ovary syndrome is the most common endocrinopathy among reproductive-aged women in the United States, affecting approximately 7% of female patients." | 1.43 | Diagnosis and Treatment of Polycystic Ovary Syndrome. ( Mortada, R; Porter, S; Williams, T, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 11 (52.38) | 24.3611 |
| 2020's | 7 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Rashid, R | 1 |
| Mir, SA | 1 |
| Kareem, O | 1 |
| Ali, T | 1 |
| Ara, R | 1 |
| Malik, A | 1 |
| Amin, F | 1 |
| Bader, GN | 1 |
| Wilkinson, LD | 1 |
| Brady, PH | 1 |
| Gin, GT | 1 |
| Rosenblum, E | 1 |
| Noubouossie Pouegue, J | 1 |
| Mvondo, MA | 1 |
| Decourt, C | 1 |
| Watanabe, Y | 1 |
| Evans, MC | 1 |
| Inglis, MA | 1 |
| Fisher, LC | 1 |
| Jasoni, CL | 1 |
| Campbell, RE | 1 |
| Anderson, GM | 1 |
| Li, Y | 1 |
| Zhu, Y | 1 |
| Li, D | 1 |
| Liu, W | 2 |
| Zhang, Y | 1 |
| Zhang, C | 1 |
| Tao, T | 1 |
| Arroyo, P | 2 |
| Ho, BS | 2 |
| Sau, L | 2 |
| Kelley, ST | 2 |
| Thackray, VG | 4 |
| Carvalho, MJ | 1 |
| Subtil, S | 1 |
| Rodrigues, Â | 1 |
| Oliveira, J | 1 |
| Figueiredo-Dias, M | 1 |
| Zhang, X | 3 |
| Xiao, H | 1 |
| E, Q | 1 |
| Gong, X | 1 |
| Li, T | 1 |
| Han, Y | 1 |
| Ying, X | 1 |
| Cherrington, BD | 1 |
| Xu, B | 1 |
| Liu, X | 1 |
| Annie, L | 1 |
| Gurusubramanian, G | 1 |
| Roy, VK | 1 |
| Skarra, DV | 1 |
| Hernández-Carretero, A | 1 |
| Rivera, AJ | 1 |
| Anvar, AR | 1 |
| Patel, R | 1 |
| Shah, G | 1 |
| Shao, YY | 1 |
| Chang, ZP | 1 |
| Cheng, Y | 1 |
| Wang, XC | 1 |
| Zhang, JP | 1 |
| Feng, XJ | 1 |
| Guo, YT | 1 |
| Liu, JJ | 1 |
| Hou, RG | 1 |
| Torres, PJ | 1 |
| Chen, A | 1 |
| Rezvanfar, MA | 3 |
| Saeedi, S | 1 |
| Mansoori, P | 1 |
| Saadat, S | 1 |
| Goosheh, M | 1 |
| Shojaei Saadi, HA | 1 |
| Baeeri, M | 2 |
| Abdollahi, M | 2 |
| Kauffman, AS | 1 |
| Ryan, GE | 1 |
| Tolson, KP | 1 |
| Glidewell-Kenney, CA | 1 |
| Semaan, SJ | 1 |
| Poling, MC | 1 |
| Iwata, N | 1 |
| Breen, KM | 1 |
| Duleba, AJ | 1 |
| Stener-Victorin, E | 1 |
| Shimasaki, S | 1 |
| Webster, NJ | 1 |
| Mellon, PL | 1 |
| Williams, T | 1 |
| Mortada, R | 1 |
| Porter, S | 1 |
| Badawy, A | 1 |
| Mosbah, A | 1 |
| Tharwat, A | 1 |
| Eid, M | 1 |
| Legro, RS | 1 |
| Kunselman, AR | 1 |
| Brzyski, RG | 1 |
| Casson, PR | 1 |
| Diamond, MP | 1 |
| Schlaff, WD | 1 |
| Christman, GM | 1 |
| Coutifaris, C | 1 |
| Taylor, HS | 1 |
| Eisenberg, E | 1 |
| Santoro, N | 1 |
| Zhang, H | 1 |
| Ahmadi, A | 1 |
| Shojaei-Saadi, HA | 1 |
| Wikström, AM | 1 |
| Bay, K | 1 |
| Hero, M | 1 |
| Andersson, AM | 1 |
| Dunkel, L | 1 |
| Nader, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment[NCT05298657] | 200 participants (Anticipated) | Observational [Patient Registry] | 2022-09-01 | Not yet recruiting | |||
| Extended Letrozole Regimen Co-treatment With Gonadotropin Releasing Hormone Antagonist Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in Poor Responders Undergoing IVF-ET. A Randomized Controlled Trial[NCT04268927] | Phase 2 | 106 participants (Anticipated) | Interventional | 2018-04-01 | Recruiting | ||
| Extended High Dose Letrozole Regimen Versus Short Low Dose Letrozole Regimen as an Adjuvant to GnRH Antagonist Protocol in the Management of Patients With Poor Ovarian Response Undergoing IVF-ET, a Randomized Controlled Trial[NCT01219153] | Phase 2 | 136 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Extended Letrozole Regimen Versus Clomiphene Citrate for Superovulation in Patients With Unexplained Infertility Undergoing Intrauterine Insemination[NCT01232075] | Phase 2 | 214 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Letrozole and Sequential Clomiphene to Improve the Outcome of Embryo Transfer in Polycystic Ovary Syndrome (PCOS) Patients[NCT02775877] | 100 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for letrozole and Hyperandrogenism
| Article | Year |
|---|---|
Polycystic ovarian syndrome-current pharmacotherapy and clinical implications.
Topics: Acupuncture; Anovulation; Eflornithine; Female; Herbal Medicine; Hirsutism; Humans; Hydroxymethylglu | 2022 |
Controversial association between polycystic ovary syndrome and breast cancer.
Topics: Androgens; Anovulation; Aromatase Inhibitors; Breast Neoplasms; Clomiphene; Contraceptives, Oral, Co | 2019 |
Ovulation induction in polycystic ovary syndrome.
Topics: Adult; Anovulation; Aromatase Inhibitors; Body Mass Index; Clomiphene; Diathermy; Female; Fertility | 2008 |
3 trials available for letrozole and Hyperandrogenism
| Article | Year |
|---|---|
Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol.
Topics: Adult; Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Estrogen Antagonists; Female; | 2009 |
Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol.
Topics: Adult; Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Estrogen Antagonists; Female; | 2009 |
Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol.
Topics: Adult; Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Estrogen Antagonists; Female; | 2009 |
Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol.
Topics: Adult; Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Estrogen Antagonists; Female; | 2009 |
Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol.
Topics: Adult; Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Estrogen Antagonists; Female; | 2009 |
Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol.
Topics: Adult; Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Estrogen Antagonists; Female; | 2009 |
Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol.
Topics: Adult; Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Estrogen Antagonists; Female; | 2009 |
Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol.
Topics: Adult; Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Estrogen Antagonists; Female; | 2009 |
Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol.
Topics: Adult; Anovulation; Aromatase Inhibitors; Clomiphene; Drug Resistance; Estrogen Antagonists; Female; | 2009 |
The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Antineoplastic Agents; Chi-Square Distribution; Clomiphene; Double-Blind Method; | 2012 |
Serum insulin-like factor 3 levels during puberty in healthy boys and boys with Klinefelter syndrome.
Topics: Adolescent; Age Determination by Skeleton; Aromatase Inhibitors; Body Height; Child; Dwarfism; Healt | 2006 |
15 other studies available for letrozole and Hyperandrogenism
| Article | Year |
|---|---|
Female Pelvic Conditions: Polycystic Ovary Syndrome.
Topics: Acne Vulgaris; Anovulation; Female; Finasteride; Gonadotropin-Releasing Hormone; Hirsutism; Humans; | 2022 |
Topics: Animals; Aromatase; Female; Humans; Hyperandrogenism; Letrozole; Moraceae; Overweight; Polycystic Ov | 2023 |
Deletion of Androgen Receptors From Kisspeptin Neurons Prevents PCOS Features in a Letrozole Mouse Model.
Topics: Androgens; Animals; Disease Models, Animal; Female; Hyperandrogenism; Kisspeptins; Letrozole; Mice; | 2023 |
Depletion of gut microbiota influents glucose metabolism and hyperandrogenism traits of mice with PCOS induced by letrozole.
Topics: Animals; Anti-Bacterial Agents; Blood Glucose; Female; Gastrointestinal Microbiome; Humans; Hyperand | 2023 |
Letrozole treatment of pubertal female mice results in activational effects on reproduction, metabolism and the gut microbiome.
Topics: Adult; Age Factors; Androgens; Animals; Aromatase Inhibitors; Bacterial Typing Techniques; Blood Glu | 2019 |
Decreased microRNA-125b-5p disrupts follicle steroidogenesis through targeting PAK3/ERK1/2 signalling in mouse preantral follicles.
Topics: Androgens; Animals; Estradiol; Estrogens; Female; Gene Expression Regulation; Hyperandrogenism; Letr | 2020 |
Inhibition of visfatin by FK866 mitigates pathogenesis of cystic ovary in letrozole-induced hyperandrogenised mice.
Topics: Acrylamides; Androgens; Animals; Blood Glucose; Cytokines; Disease Models, Animal; Female; Hyperandr | 2021 |
Hyperandrogenemia Induced by Letrozole Treatment of Pubertal Female Mice Results in Hyperinsulinemia Prior to Weight Gain and Insulin Resistance.
Topics: Animals; Eating; Energy Metabolism; Female; Glucose; Hyperandrogenism; Hyperinsulinism; Insulin Resi | 2017 |
Insulin Sensitizers Modulate GnRH Receptor Expression in PCOS Rats.
Topics: Animals; Body Weight; Carboxymethylcellulose Sodium; Diet, High-Fat; Female; Glucose Tolerance Test; | 2018 |
Shaoyao-Gancao Decoction alleviated hyperandrogenism in a letrozole-induced rat model of polycystic ovary syndrome by inhibition of NF-κB activation.
Topics: Animals; Disease Models, Animal; Drugs, Chinese Herbal; Female; Gene Expression Regulation; Humans; | 2019 |
Exposure to a Healthy Gut Microbiome Protects Against Reproductive and Metabolic Dysregulation in a PCOS Mouse Model.
Topics: Animals; Anovulation; Aromatase Inhibitors; Disease Models, Animal; Dysbiosis; Female; Gastrointesti | 2019 |
Dual targeting of TNF-α and free radical toxic stress as a promising strategy to manage experimental polycystic ovary.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Disease Models, Animal; Drug Therapy, C | 2016 |
A Novel Letrozole Model Recapitulates Both the Reproductive and Metabolic Phenotypes of Polycystic Ovary Syndrome in Female Mice.
Topics: Animals; Corpus Luteum; Diestrus; Enzyme Inhibitors; Estrous Cycle; Female; Hyperandrogenism; Hypoth | 2015 |
Diagnosis and Treatment of Polycystic Ovary Syndrome.
Topics: Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperandrogenism; Hypogl | 2016 |
Molecular mechanisms of a novel selenium-based complementary medicine which confers protection against hyperandrogenism-induced polycystic ovary.
Topics: Animals; Antioxidants; Biomarkers; Estradiol; Female; Hyperandrogenism; Letrozole; Lipid Peroxidatio | 2012 |